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BACKGROUND: TheSCREEN (Skin Cancer Research to provide Evidence for Effectivenessof Screening in Northern Germany) project
involved population-wide skin cancer screening with whole-body examination by general physicians and dermatologists. It was
conducted in the German state of Schleswig-Holstein (July 2003–June 2004), but not in the German state of Saarland.
METHODS: The population-based registries of Schleswig-Holstein and Saarland provided data on melanoma incidence before, during,
and after SCREEN to assess the association of skin cancer screening with incidence.
RESULTS: Approximately 19%of the Schleswig-Holstein population participated in SCREEN (women: 27%,men: 10%). A total of 52%
of all melanomas diagnosed during SCREEN in Schleswig-Holstein were detected as part of the project. Melanoma incidence
increased duringSCREEN (invasive melanoma in women: þ 8.9 per 100000 (95%confidence intervals (CI): 6.1; 11.7); men: þ 4.0
per 100000 (95%CI: 1.6; 6.4)) and decreased afterwards (women: 10.6 per 100000 (95%CI: 13.3; 7.9); men: 4.1 per
100000 (95%CI:6.5;1.7)).Similar changeswere not observed in Saarland that had no such project.Thedifferencesbetween the
two states were greatest among women, the group with the greater SCREEN participation.
CONCLUSION: The SCREEN project had a substantial impact on melanoma incidence. This is consistent with the impact of effective
screening for other cancers.
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Cutaneous melanoma is a public health problem of increasing
magnitude among light-skinned populations worldwide (Geller et al,
2007; Garbe and Leiter, 2009; Horner et al, 2009; RKI and GEKID,
2010). In 2003–2004, the SCREEN project (Skin Cancer Research to
provide Evidence for Effectiveness of Screening in Northern
Germany) was conducted in Schleswig-Holstein, Germany. The
success of this feasibility project (Breitbart et al, 2011) led to the
implementation of the national Skin Cancer Early Detection
Program. This programme has an initial 5-year trial period and
commenced in July 2008.
In population-based screening programmes such as those for
breast or cervical cancer, incidence increases after the uptake of
screening, due to the detection of prevalent cancers and other
factors (Canfell et al, 2006; Anttila et al, 2008; Hofvind et al, 2008;
van der Aa et al, 2008; Pollan et al, 2009, 2010), and declines when
screening activities end.
To date, there are no reports on incidence effects of population-
based skin cancer screening programmes using whole-body
examination. Herein, we document participation in the SCREEN
project and population-based melanoma incidence rates before,
during, and after SCREEN in Schleswig-Holstein. Incidence is
compared with Saarland, a federal state in southwestern Germany
with a long tradition of and a high-completeness of cancer
registration, but without a population-based screening during the
SCREEN’s inception in 2003.
MATERIALS AND METHODS
The SCREEN project
The population-based SCREEN project was a 12-month skin
cancer screening intervention (whole-body examination conducted
by either general physicians and/or dermatologists; July 2003–
June 2004). Eligible persons were residents of Schleswig-Holstein,
aged X 20 years, and policyholders of statutory health insurance.
Persons receiving skin cancer care were not eligible. Participants
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chose between non-dermatologist physicians and dermatologists
for their initial whole-body skin examination. If a non-dermatol-
ogist found a suspicious skin lesion or classified the screenee as at
increased risk for skin cancer, he was then referred to a
dermatologist to receive a second whole-body examination. Only
dermatologists were allowed to excise lesions. All screening
physicians received a mandatory 8-h training course before the
SCREEN (Breitbart et al, 2011).
Ethics approval was not required as SCREEN was an integral
part of the standard medical care. The SCREEN participants gave
written informed consent for data storage and analysis; participa-
tion was voluntary.
Statistical analysis
Crude tumour detection rates are given as melanoma cases per
100000 screenees. Melanomas reported to the Cancer Registry are
presented as age-standardised incidence rates per 100000 inhabi-
tants (ASR Europe). Poisson-based confidence intervals (95% CI)
were computed according to Dobson et al (1991). Student’s t-tests
(R) provided approximate P-values for the comparison of absolute
changes in Schleswig-Holstein and Saarland (R Development Core
Team, 2010).
Several time periods were defined for the analysis: pre-SCREEN
(January 1998–December 2000; period without screening in
Schleswig-Holstein), SCREEN (July 2003–June 2004; period in
which screening was conducted in Schleswig-Holstein), and post-
SCREEN (January 2005–December 2007; period without formal
screening activities). The years 2001–2002 were not included,
because pilot projects in advance of the full-scale SCREEN project
began in Schleswig-Holstein in 2001.
RESULTS
Participation in SCREEN
Of 1.88 million eligible citizens, 19.2% received skin cancer
screening during the 1-year screening period (27.0% of women,
10.4% of men; Table 1).
Melanoma findings in Schleswig-Holstein
During the SCREEN period, 1116 incident melanomas (31% in situ)
were reported to the Schleswig-Holstein Cancer Registry (Table 2).
Of these, 585 melanomas (also 31% in situ) were detected as part of
the SCREEN project, equaling 52% of all melanomas reported
during this period (56% in women, 46% in men).
Although men comprised 26.4% of all screenees, they repre-
sented 36.1% of all 585 melanomas detected during the SCREEN.
The difference between the proportion of all 360 288 screenees and
the proportion of all SCREEN-detected melanomas was highest in
the subgroup of men aged X 50 years (16% of all screenees, 29% of
all SCREEN-detected melanomas; Table 1).
Time trends in melanoma incidence rates
Throughout all time periods, the incidence of in situ and invasive
melanomas was higher in Schleswig-Holstein than in Saarland
(Table 3). Women in Schleswig-Holstein compared with those
from Saarland experienced sharper increases in incidence during
the SCREEN period and sharper decreases in incidence in the post-
SCREEN period. In Schleswig-Holstein women, the incidence
changes (e.g., absolute differences in incidence rates) were
substantial and statistically significant. In Schleswig-Holstein
men, incidence changes were significant and similar in direction,
but less pronounced compared with women. The differences
between Schleswig-Holstein and Saarland men regarding the
absolute differences in incidence rates were neither in the SCREEN
period nor in the post-SCREEN period significant.
DISCUSSION
The SCREEN project was a population-based skin cancer-
screening programme using whole-body examinations. Although
incidence changes were observed in Schleswig-Holstein in a
temporal association with SCREEN activities, no such changes
were seen in Saarland (region without SCREEN; exception in men
changes in-situ melanoma incidence). Differences between the two
regions were greatest among women, the group with higher
participation in SCREEN.
Participation in SCREEN
We sought to compare participation rates from Schleswig-Holstein
with earlier surveys that ascertained whether they ‘ever had skin
cancer screening’ or not. The proportion of people reporting to
have had skin cancer screening in both Austria and the US was
somewhat lower than the participation proportion achieved in the
1-year SCREEN project (Haidinger et al, 2009; Lakhani et al, 2009).
As known from other cancer early-detection programmes, some
population groups (e.g., women, high socio-economic status, and
urban dwellers) are more responsive to such programmes than
Table 1 Description of SCREEN project participants, confirmed
diagnoses of MM (absolute, relative frequencies), and population-based
participation rates
W omen
(n¼ 265306)
Men
(n¼ 94982)
Mean age (s.d.) 48.2 (16.2) 53.9 (15.7)
Age group (years) (n (%))a
p 34 59513 (22.4) 12043 (12.7)
35–49 86375 (32.6) 25133 (26.5)
50–64 70117 (26.4) 29765 (31.3)
X 65 49301 (18.6) 28050 (29.5)
Number of histopathologically confirmed MM (n (%))a
In total 372 (0.14) 213 (0.22)
Stratified according to age-group (years)
p 34 58 (0.09) 18 (0.15)
35–49 118 (0.13) 24 (0.09)
50–64 109 (0.16) 72 (0.24)
X 65 87 (0.18) 99 (0.35)
Crude MM detection rates per 100000 screeneesb
In total 140.2 221.1
Stratified according to age-group (years)
p 34 97.5 149.5
35–49 136.6 91.5
50–64 155.5 241.9
X 65 176.5 345.8
Population-based participation (%)c
In total 27.0 10.4
Stratified according to age-group (years)
p 34 29.0 5.7
35–49 30.6 8.6
50–64 30.0 12.8
X 65 19.0 15.5
Abbreviations: MM¼ melanoma; SCREEN ¼ Skin Cancer Research to provide
Evidence for Effectiveness of Screening in Northern Germany. aPercentages are
based on the total number of screenees in sex and sex-by-age-groups, respectively.
bNumber of MM findings in a particular subgroup/divided by number of screenees
in subgroup multiplied by 100000. cPercentages are based on the total number of
eligible persons in Schleswig-Holstein in sex and sex-by-age groups, respectively.
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others (Scheffer et al, 2006; von Wagner et al, 2009; Palencia et al,
2010; Sprague et al, 2010). Likewise in SCREEN, women show a
substantially higher participation compared with men (Haidinger
et al, 2009). Similar patterns have been observed in the
American Academy of Dermatology National Melanoma/Skin
Cancer Screening Program (Goldberg et al, 2007) or the German
colonoscopy screening (Altenhofen et al, 2009).
Men who participate in skin cancer screening programmes tend to
be high-risk individuals (Jemal et al, 2007; Paoli et al, 2009; Breitbart
et al, 2011). In the American Academy of Dermatology programme,
men X 50 years comprised 23% of all screenees, but accounted for
32% of all suspected melanomas (Goldberg et al, 2007).
Melanoma epidemiology
A significant increase in melanoma incidence was observed
between pre SCREEN and SCREEN, whereas in the 3-year period
following SCREEN, especially invasive melanoma incidence
returned to baseline levels. In contrast in Saarland, we observed
a general small incidence increase from 2000 to 2007 for both in
situ and invasive melanomas.
The significant increase of in situ melanomas in men reported
here can be contributed to a chance finding due to small absolute
numbers of in situ melanomas and year-to-year fluctuation. In
Saarland, in situ incidence has been increasing steadily since 1980.
However, from 1998 to 2002, a ‘dent’ is seen in the in situ
incidence, generating the significant effect. In sensitivity analyses
with differing time periods as Saarland’s baseline incidence, the
increase was non-significant.
The observed increase in incidence in Schleswig-Holstein is
consistent with the hypothesis that after implementing a screening
programme, an incidence rise (Hofvind et al, 2008), and with
findings from breast cancer and cervical cancer screening
interventions (Anttila et al, 2008; Hofvind et al, 2008; van der Aa
et al, 2008; Pollan et al, 2010). The absolute change in incidence
during the SCREEN period was higher in women than in men, as
were respective proportions of the population participating in
SCREEN. However, men with clinical symptoms are more likely to
attend to skin cancer screening (Geller et al, 2002; Janda et al,
2006; Breitbart et al, 2011). This may have contributed to the
increase in invasive melanoma incidence, but not in melanoma
in situ incidence on the population level.
Table 2 MM that were reported to the cancer registry Schleswig-
Holstein for the SCREEN period and the proportion of melanomas
detected during SCREEN
W omen Men
MM reported to cancer registry for the SCREEN period
Total number of MM 659 457
In situ MM (n (%)) 220 (33.4) 127 (27.8)
Invasive MM (n (%)) 439 (66.6) 330 (72.2)
Histopathologically confirmed MM in SCREEN
Total number of MM 372 210
In situ MM (n (%)) 131 (35.2) 49 (23.3)
Invasive MM (n (%)) 241 (64.8) 161 (76.7)
Proportion of MM that were detected during SCREEN (%)
All MM 372/659 (56.4) 210/457 (45.9)
Stratified accordingto age-group (years)
p 34 58/99 (58.6) 18/34 (52.9)
35–49 118/182 (64.8) 23/64 (35.9)
50–64 109/190 (57.4) 72/156 (46.2)
X 65 87/188 (46.3) 97/203 (47.8)
In situ MM 131/220 (59.5) 49/127 (38.6)
Stratified according to age-group (years)
p 34 28/39 (71.8) 7/19 (36.8)
35–49 40/68 (58.8) 9/16 (56.3)
50–64 40/61 (65.6) 17/41 (41.5)
X 65 23/52 (44.2) 16/51 (31.4)
Invasive MM 241/439 (54.9) 161/330 (48.8)
Stratified according to age-group (years)
p 34 30/60 (50.0) 11/15 (73.3)
35–49 78/114 (68.4) 14/48 (29.2)
50–64 69/129 (53.5) 55/115 (47.8)
X 65 64/136 (47.1) 81/152 (53.3)
Abbreviations: MM¼ melanoma; SCREEN ¼ Skin Cancer Research to provide
Evidence for Effectiveness of Screening in Northern Germany.
Table 3 Age-standardised incidence rates(n/100000 (95%CI)a; ASR(Europe)) of MM pre SCREEN, during the SCREEN project and post SCREEN, and
absolute differences in incidence rates
SH SL
P for compar ison
of SH and SL
W omen Men W omen Men W omen Men
Incidence rate ASR(Europe)
Pre-SCREEN period (January 1998–December 2000)
In situ MM (ICD-10 D03) 5.7 (5.0; 6.4) 3.7 (3.2; 4.3) 2.4 (1.8; 3.2) 1.0 (0.6; 1.6) o 0.001 o 0.001
Invasive MM (ICD-10 C43) 16.8 (15.7; 18.0) 15.2 (14.1; 16.4) 9.2 (7.8; 10.6) 10.7 (9.3; 12.4) o 0.001 o 0.001
SCREEN period (July 2003–June 2004)
In situ MM (ICD-10 D03) 13.3 (11.5; 15.2) 7.7 (6.4; 9.2) 3.5 (2.1; 5.3) 3.1 (1.8; 4.8) o 0.001 o 0.001
Invasive MM (ICD-10 C43) 25.7 (23.2; 28.3) 19.2 (17.2; 21.5) 10.9 (8.4; 13.8) 11.8 (9.2; 14.9) o 0.001 0.003
Post SCREEN and pre SCEDP period (January 2005–December 2007)
In situ MM (ICD-10 D03) 10.4 (9.5; 11.4) 6.6 (5.9; 7.3) 4.0 (3.1; 5.0) 3.6 (2.8; 4.6) o 0.001 o 0.001
Invasive MM (ICD-10 C43) 15.1 (14.0; 16.2) 15.1 (14.1; 16.3) 12.2 (10.6; 13.9) 11.5 (10.0; 13.1) 0.044 0.002
Absolute differences in incidence rates ASR(Europe) (observed – preceding incidence as indicated above)
SCREEN period
In situ MM (ICD-10 D03) 7.6 (5.6; 9.6) 4.0 (2.5; 5.5) 1.1 ( 0.5; 2.7) 2.1 (0.6; 3.6) o 0.001 0.164
Invasive MM (ICD-10 C43) 8.9 (6.1; 11.7) 4.0 (1.6; 6.4) 1.7 ( 1.3; 4.7) 1.1 ( 2.0; 4.2) 0.005 0.373
Post SCREEN/pre SCSperiod
In situ MM (ICD-10 D03)  2.9 ( 5.0; 0.8)  1.1 ( 2.7; 0.5) 0.5 ( 1.2; 2.2) 0.5 ( 1.2; 2.2) 0.019 0.264
Invasive MM (ICD-10 C43)  10.6 ( 13.3;  7.9)  4.1 ( 6.5;  1.7) 1.3 ( 1.8; 4.4)  0.3 ( 3.4; 2.8) o 0.001 0.252
Abbreviations: ASR¼ age-standardised incidence rates; CI¼ confidence intervals; MM¼ melanoma; SCS¼ skin cancer screening; SCEDP¼ Skin Cancer Early
Detection Program; SCREEN ¼ Skin Cancer Research to provide Evidence for Effectiveness of Screening in Northern Germany; SH¼ Schleswig-Holstein; SL¼ Saarland.
aPoisson-based 95%CI.
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The incidence differences observed within Germany with the
highest incidence rates in northern Germany (e.g., Schleswig-
Holstein) and lower rates in the south (e.g., Saarland) match the
general European pattern with the highest incidence rates in
Scandinavia and lower incidence rates in Central Europe (WHO
and IARC, 2011).
Strengths and limitations
An important strength of the SCREEN project is the high
acceptance among both the population and the physicians (98%
of dermatologists and 64% of eligible non-dermatologists partici-
pated (Breitbart et al, 2011)). Further, the population-based
Cancer Registries of Schleswig-Holstein and Saarland have an
excellent history of cancer registration, with both registering
more than 95% of all expected melanomas. SCREEN offers the
opportunity to compare incidence in a region with and a region
without population-based skin cancer screening pre-, during, and
post-screening activities.
As not all statutory health insurances participated in SCREEN,
1.65 million of 1.88 million adults living in Schleswig-Holstein
were eligible to be screened. However, the true age- and sex-
distribution is only known for the total population of 1.88 million
adults. Hence, the estimate of a 19% participation rate (i.e.,
persons with a documented SCREEN examination in the total
population of 1.88 million) might be too conservative. Further-
more, patients without informed consent, policyholders of non-
participating health insurances, or patients who saw their
physician for other health reasons might also have benefitted
from the improved ability of SCREEN physicians to detect skin
cancer.
Further, we assume that an ad-hoc participation rate of at least
19% in the first year and the 50% capture rate of all melanomas
reported to the Cancer Registry Schleswig-Holstein within
SCREEN could impact the incidence as reported herein.
CONCLUSION
The SCREEN programme was associated with increased melanoma
incidence compared with the pre- and post-SCREEN rates in
Schleswig-Holstein and compared with Saarland, where popula-
tion-based screening did not take place. This effect was strongest
among women who were nearly three times as likely to participate
as men. The reported experience is consistent with observations in
effective breast and cervical cancer screening (Canfell et al, 2006;
Anttila et al, 2008; Hofvind et al, 2008; van der Aa et al, 2008;
Pollan et al, 2009, 2010). It suggests that SCREEN was a similarly
effective programme for melanoma.
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